MedTrace Logo

Blood Pressure Outcomes With Liraglutide Therapy

NCT01755572 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2015-03-25

No results posted yet for this study

Summary

Purpose:

The purpose of this study is to further study the mechanism by which liraglutide, a relatively new anti-hyperglycemic medication, might lower blood pressure in patients with Type 2 diabetes and high blood pressure.

Conditions

Interventions

DRUG

Liraglutide

Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.

DRUG

Placebo

Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.

Sponsors & Collaborators

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • Mount Sinai Hospital, Canada

    lead OTHER

Principal Investigators

  • Dr. Daniel J. Drucker, MD · Samuel Lunenfeld Research Institute

  • Dr. Julie A. Lovshin, MD, PhD · Samuel Lunenfeld Research Institute

  • Dr. Bernard Zinman, MD · Leadership Sinai Centre for Diabetes

  • Dr. Alexander A. Logan, MD · Samuel Lunenfeld Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-01-31
Completion
2014-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01755572 on ClinicalTrials.gov